MENU
JUN 20, 2019 10:30 AM PDT

Beyond the Score: Tools for Pan-Biomarker Analysis and TMB Estimation Enabling Deeper Understanding of Somatic Alterations that Contribute to Cancer Initiation, Progression and Recurrence

Sponsored by: QIAGEN
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Product Owner of QIAGEN Clinical Insight (QCI™) Intepret
    Biography
      Dr. Beate Litzenburger is the product owner of QIAGEN Clinical Insight (QCI™) Intepret. Prior to joining the QIAGEN team, Dr. Litzenburger led clinical decision support for several next generation sequencing research protocols at MD Anderson Cancer Center. In this role, Dr. Litzenburger was responsible for providing alteration interpretation, drug, and clinical trial options to clinicians. Dr. Litzenburger received her Ph.D. in molecular genetics from the University of Aachen in Germany and was a National Cancer Institute-supported post-doctoral fellow in the Department of Clinical Cancer Prevention at MD Anderson Cancer Center.
    • Senior Global Product Manager, QIAGEN
      Biography
        Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.

      Abstract

      Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. 

      In the first half of the webinar, we introduce the QIAseq Tumor Mutational Burden (TMB) Panel, a comprehensive next-generation sequencing (NGS) assay that targets the full coding region of 486 genes implicated in the pathogenesis of solid tumors and can be boosted to add 27 microsatellite instability (MSI) markers. From optimized primer design based on the robust UMI-enabled single primer extension (SPE) chemistry, which reduces false positives and eliminates duplicate reads, and now coupled with the CLC Genomics Workbench, the QIAseq Tumor Mutation Burden Panel ensures TMB estimation consistent with best practices as reported by the Friends of Cancer Research (Genes, Chromosomes & Cancer, 2019). With QIAGEN Clinical Insight (QCI™) – Interpret, insights for variants detected, based on private and publicly available data sources, are provided, enabling a better understanding of these variants and their role in tumor initiation, growth, spread and recurrence.

      In the second half we present a scalable bioinformatics solution for the interpretation of somatic mutations. Cancer laboratories need rapid and reliable interpretation of identified genomic alterations. One of the challenges they face is producing standardized, reproducible interpretation and reporting of the most current and actionable information. QIAGEN Clinical Insight (QCI™) Interpret enables labs to deliver evidence-based, actionable insights and reporting of variants and TMB and MSI scores from tumor genomic profiles. We will discuss the benefits of automating guidelines (AMP/ASCO/CAP and ACMG/AMP) for vetting somatic cancer alterations for biological and actionable relevance while providing the evidence behind each automated classification via direct links to the source, facilitating insights that improve clinical trial matching.

      Learning Objectives: 

      1. Learn how the coupled solution of UMI-enabled single primer extension (SPE) and the well renowned CLC algorithms for secondary analysis enables the coverage and high confidence detection of variants, even those at low frequency (as low as 0.4%) while minimizing impact of PCR duplicates and false positives which could inflate TMB scores
      2. Learn how the QIAGEN Clinical Insight (QCI™)- Interpret clinical decision support platform can enable rapid and consistent reporting of variant pathogenicity and actionability, resulting in better clinical trial matching.


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      Loading Comments...
      Show Resources